中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
甲基4-羟基-2-甲氧基-6-甲基-苯甲酸酯 | methyl 4-hydroxy-2-methoxy-6-methylbenzoate | 3465-63-2 | C10H12O4 | 196.203 |
—— | 2-methoxy-4-methoxycarbonyloxy-6-methyl-benzoic acid methyl ester | 866996-98-7 | C12H14O6 | 254.24 |
石茸酸 | umbilicaric acid | 30666-92-3 | C25H22O10 | 482.444 |
The chemical examination of acetone extract of Dirinaria consimilis resulted in isolation of six depsides of which two novel metabolites namely antarvediside A (1) and antarvediside B (2) and four known metabolites i.e. sekikaic acid (3), atranorin (4), divaricatic acid (5) and 2’-O-methyl divaricatic acid (6). From the pharmacological screening of the isolates (1-6), it was found that 1 and 2 exhibited better inhibition of ABTS and superoxide free radicals than that of the standard and compound 4 showed significant inhibition of protein denaturation with IC50 value of 390 mg/mL with respect to indomethacin with 110 mg/mL. From the SRB assay results, the better IC50 values was determined by compound 2 of 10.5, 11.50 and 12.50 μg/mL on HeLa, MCF-7 and FADU cancer cell lines, respectively. Thus, the outcomes revealed that the D. consimilis is a new source to treat free radicals, inflammation and cancer.